Shattuck Labs (STTK) Other financing activities (2020 - 2026)

Shattuck Labs (STTK) posted quarterly Other financing activities of $59000.0 for Q1 2026, down 48.25% quarter-over-quarter from $114000.0 in Q4 2025.

Shattuck Labs (STTK) Other financing activities (2020 - 2026) Analysis & Trends

Shattuck Labs (STTK) has reported Other financing activities for 7 consecutive years, with $59000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Other financing activities changed N/A year-over-year to $59000.0; the TTM figure through Mar 2026 stood at $198000.0 (down 69.35% YoY), while the FY2025 annual figure was $139000.0, down 88.92% from the prior year.
Other financing activities eased to $59000.0 in Q1 2026 per STTK's latest filing, from $114000.0 in the prior quarter.
Across five years, Other financing activities topped out at $691000.0 in Q2 2024 and bottomed at -$72000.0 in Q4 2024.
Historically, Other financing activities has averaged $141533.3 across 5 years, with a median of $33000.0 in 2023.
On a YoY basis, Other financing activities climbed as much as 1993.94% in 2024 and fell as far as 117.73% in 2024.
Shattuck Labs' Other financing activities stood at $27000.0 in 2022, then soared by 1403.7% to $406000.0 in 2023, then slumped by 117.73% to -$72000.0 in 2024, then jumped by 258.33% to $114000.0 in 2025, then slumped by 48.25% to $59000.0 in 2026.
Business Quant data shows STTK's Other financing activities at $59000.0 in Q1 2026, $114000.0 in Q4 2025, and $17000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Shattuck Labs	962.96 Mn	962.96 Mn	-

Download Data